ArticleAmerican journal of translational research2025
Iguratimod in combination with conventional therapy suppresses inflammation and improves joint structure and function in rheumatoid arthritis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic efficacy of iguratimod in combination with conventional therapy in patients with rheumatoid arthritis (RA) and to explore changes in hematological and ultrasonographic parameters, as well as their correlations with disease activity.
methodsThis single-center, retrospective clinical study involved 79 RA patients, including 49 in the combination therapy group (iguratimod plus conventional therapy) and 30 in the standard therapy group (conventional therapy alone). The following parameters were assessed at baseline and after 12 weeks of treatment: the Disease Activity Score in 28 joints (DAS28), Visual Analogue Scale (VAS) scores, inflammatory markers (high-sensitivity C-reactive protein, hs-CRP; erythrocyte sedimentation rate, ESR; rheumatoid factor, RF), joint function grades, and ultrasonographic features-including synovial thickness, cartilage thickness, blood flow signals, joint effusion, and synovial arterial resistance index (RI). Adverse events were recorded to assess drug safety.
resultsAfter 12 weeks of treatment, the overall clinical efficacy rate was significantly higher in the combination therapy group than in the standard therapy group (95.92% vs. 76.67%, P<0.05). Patients in the combination therapy group showed significant decreases in DAS28, VAS scores, morning stiffness duration (all P<0.05). After 12 weeks of treatment, the levels of serum hs-CRP, ESR and RF levels in the combined therapy group decreased significantly and were lower than those in the standard therapy group (all P < 0.05). Ultrasonography revealed marked reductions in synovial thickness, joint effusion, and synovial blood flow signals in the combination therapy group after treatment, along with a reduction in RI (P<0.05). Moreover, the proportion of Grade I joint function increased, while Grade IV proportion decreased significantly in the combination therapy group (P<0.05). The incidence of adverse events was comparable between groups, and no serious events occurred (P>0.05).
conclusionIguratimod combined with conventional therapy effectively alleviates inflammation, improves joint function, and mitigates structural damage in RA patients, with a favorable safety profile. Dynamic monitoring of hematological and imaging parameters provides a more comprehensive assessment of disease activity, supporting the clinical utility of iguratimod-based combination therapy in RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.